Track topics on Twitter Track topics that are important to you
Since our inception in 1996, Royalty Pharma has expanded the traditional parameters that define a pharmaceutical company. By focusing on intellectual property - the key to premium pricing and profits in the pharmaceutical industry - Royalty Pharma has become the global leader in the acquisition of royalty interests. Royalty Pharma has assembled a well-diversified and well-balanced portfolio of royalties in leading biopharmaceutical products achieving rapid and profitable growth with a managed risk profile.
The origins of Royalty Pharma can be traced to the 1980s when certain members of Royalty Pharma’s Investment Committee and Management Team pioneered the use of royalty interests to fund the clinical development of several leading biotechnology products through “Research & Development Partnerships.” In 1993 and 1994, when these R&D partnerships started earning royalties, two product-specific "proof of principle" acquisition vehicles were established to acquire royalty interests in Neupogen® and ReoPro®. The success of those efforts led to the founding in 1996 of Royalty Pharma’s predecessors: Pharmaceutical Royalties, LLC (Delaware, USA) and Pharmaceutical Royalty Investments, Ltd. (Bermuda). Subsequently in 2003, Royalty Pharma was established as an Irish Unit Trust, to consolidate the operations of its predecessors and to facilitate a new business model for the Company.
Portfolio (view latest list)
Product Indication Royalty - Seller
Approved / In Development
Neupogen/Neulasta Cancer, white blood cell stimulant MSK
Remicade - US & Int'l Rheumatoid Arthritis (RA), UC, Crohn´s, PsA, AS, Psoriasis NYU
Humira Rheumatoid Arthritis (RA), UC, AstraZeneca
Rituxan - US B-cell Lymphoma, RA, XOMA
Atripla/Truvada/Emtriva (3) HIV/AIDS Emory
Thalomid Multiple Myeloma Entre Med
Lyrica Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Onset Seizures and Fibromyalgia Northwestern University
Prezista HIV/AIDS PharmaCo
Letairis/Volibris PAH PharmaCo
RotaTeq Rotavirus Vaccine CHOP
Cubicin cSSSI, Bacteremia, Endocarditis Not Disclosed
Savella Fibromyalgia Cypress Bioscience
Myozyme/Lumizyme Pompe Disease Academic Institution
Lexiscan Pharmacological Stress Agent for MPI Not Disclosed
Januvia/Janumet Diabetes Astellas
Onglyza/Kombiglyze Diabetes Astellas
Galvus/Eucreas Diabetes Astellas
Nesina Diabetes Astellas
Tradjenta Diabetes Astellas
TOBI Anti-Infectives (cystic fibrosis) Inventor
Viviant 2nd gen. SERM: Osteoporosis Ligand
Cimzia Rheumatoid Arthritis (RA), Crohn's Nektar Therapeutics
Mircera Chronic Kidney Disease (CKD) Nektar Therapeutics
Vosaroxin Acute Myeloid Leukemia (AML) Sunesis
Tecfidera Psoriasis, Multiple Sclerosis Fumapharm AG Shareholders
Conbriza/Aprela (4) 2nd gen. SERM: Osteoporosis Ligand
Fablyn (4) 2nd gen. SERM: Osteoporosis Ligand
Source: Royalty Pharma
110 East 59th Street
33rd Floor Suite 3300
United States of America
Royalty Pharma’s $11 per-share bid for Elan is too low, according to Elan’s management and industry analysts.
Life Sciences Jobs ...
Life Sciences Jobs ...
For Elan Investors, A Choice Between A Sure Thing Or A High-Risk Play
In this informative panel discussion, Fintan Walton talks with 3 members of PharmaVentures’ deal advisory team about Royalty Rates, particularly the valuation of deals in the pharmaceutical and biot...
Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Ph...
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 2017 report is your onestop source for providing realdeal information on hundreds of transactions, including the technology license...
The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 20102017 report provides comprehensive understanding and unprecedented access to the royalty financing a...
Fluoride Chewable Tablets 0.5 mg
Fluoride Chewable Tablets 1 mg
Metoprolol Tartrate Tablets, USP
Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )
After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as ...
To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.
The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...
Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...
Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...
To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.
A pioneer in the field when launched in 1992, Drug Royalty was the first firm to provide royalty-based financing in the life sciences sector and the first to complete royalty transactions with invento...
Since our inception in 1996, Royalty Pharma has expanded the traditional parameters that define a pharmaceutical company. By focusing on intellectual property - the key to premium pricing and profit...
Our diversified team of investment professionals is dedicated to meeting the specific needs of each client, and with our extensive experience in the healthcare and financial industries, Capital Royalt...
Drug Royalty is an innovative and profitable Canadian company involved in the international life science industry. Established in 1992, DRC was designed to participate in the growth from the global he...
DRI is a pioneer and global leader in healthcare royalty investing and has completed transactions with large global pharmaceutical companies, biotechnology companies, universities...
We have published hundreds of Royalty Pharma news stories on BioPortfolio along with dozens of Royalty Pharma Clinical Trials and PubMed Articles about Royalty Pharma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Royalty Pharma Companies in our database. You can also find out about relevant Royalty Pharma Drugs and Medications on this site too.
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...